Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)

Bayer

Status: Completed

Conditions: Ophthalmology, Macular Degeneration

Treatments: Drug: Ranibizumab

Study type: Observational

Funder types: Industry

Identifiers

NCT01447043

15913

NN1101 (Other Identifier)

Details and patient eligibility

About

Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and August 31, 2009 must be consecutively screened and, if eligible, enrolled. Patients will be followed up at maximum until August 31, 2011. Switch to any other Anti vascUlar endothelial growth factor (anti VEGF) treatment will be documented and followed up. For each patient, demographics, medical history, administered treatments, results of ocular and visual assessments and other tests (where available) will be documented.

Enrollment: 2,609 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of wet age-related macular degeneration
• Start of Anti vascUlar endothelial growth factor (anti VEGF) therapy with ranibizumab between January 1, 2009 and August 31, 2009
• Informed consent form signed, where required

Exclusion criteria

• Participation in an investigational study during anti-VEGF therapy (from start up to August 31, 2011) that involved treatment with any drug or medical device

Trial design

2,609 participants in 1 patient group

Group 1

Treatment:

Drug: Ranibizumab